Press Releases

Press Releases

Press Releases

March 21, 2018
LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics United Kingdom (UK) Ltd today announced that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), for the
March 15, 2018
Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year Ionis Chief Business Officer Sarah Boyce will join
March 12, 2018
CAMBRIDGE, Mass. and CARLSBAD, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), and Ionis Pharmaceuticals, Inc. , today announced the presentation of a poster summarizing results from the completed Phase
March 6, 2018
CAMBRIDGE, Mass. , March 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that
February 28, 2018
Upcoming global FCS Summit will enable advocates to connect and build a stronger FCS community CAMBRIDGE, Mass. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients
February 26, 2018
Preparing for mid-2018 approval and launch of volanesorsen for FCS in the US, EU and Canada Advancing the pipeline with four Phase 2 trials underway and data planned from two studies in 2018 Conference Call Webcast Monday, February 26 , 4:30 p.m. ET at www.akceatx.com CAMBRIDGE, Mass. , Feb.
February 15, 2018
Advisory Committee Meeting tentatively scheduled for May 10, 2018 CAMBRIDGE, Mass. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic
February 12, 2018
Webcast scheduled for Monday, February 26 at 4:30p.m. Eastern Time CAMBRIDGE, Mass. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious
February 7, 2018
CAMBRIDGE, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), today announced it had completed enrollment of a Phase 2b clinical study of investigational drug AKCEA-APO(a)-L Rx . Akcea is conducting the study in patients with high Lp(a) and established cardiovascular